PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma
Article in Cancer Letters (May 2024)
The most recent citing publications are shown below. View all 12 publications that cite this research output on Dimensions.
Article in Cancer Letters (May 2024)
Preprint in Research Square (March 2024)
Preprint in bioRxiv (March 2024)